<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39459940</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>13</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Efficacy of Integrase Strand Transfer Inhibitors and the Capsid Inhibitor Lenacapavir against HIV-2, and Exploring the Effect of Raltegravir on the Activity of SARS-CoV-2.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1607</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16101607</ELocationID><Abstract><AbstractText>Retroviruses perpetuate their survival by incorporating a copy of their genome into the host cell, a critical step catalyzed by the virally encoded integrase. The viral capsid plays an important role during the viral life cycle, including nuclear importation in the case of lentiviruses and integration targeting events; hence, targeting the integrase and the viral capsid is a favorable therapeutic strategy. While integrase strand transfer inhibitors (INSTIs) are recommended as first-line regimens given their high efficacy and tolerability, lenacapavir is the first capsid inhibitor and the newest addition to the HIV treatment arsenal. These inhibitors are however designed for treatment of HIV-1 infection, and their efficacy against HIV-2 remains widely understudied and inconclusive, supported only by a few limited phenotypic susceptibility studies. We therefore carried out inhibition profiling of a panel of second-generation INSTIs and lenacapavir against HIV-2 in cell culture, utilizing pseudovirion inhibition profiling assays. Our results show that the tested INSTIs and lenacapavir exerted excellent efficacy against ROD-based HIV-2 integrase. We further evaluated the efficacy of raltegravir and other INSTIs against different variants of SARS-CoV-2; however, contrary to previous in silico findings, the inhibitors did not demonstrate significant antiviral activity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kiarie</LastName><ForeName>Irene Wanjiru</ForeName><Initials>IW</Initials><AffiliationInfo><Affiliation>Laboratory of Retroviral Biochemistry, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Doctoral School of Molecular Cell and Immune Biology, University of Debrecen, 4032 Debrecen, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoffka</LastName><ForeName>Gyula</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Laboratory of Retroviral Biochemistry, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Doctoral School of Molecular Cell and Immune Biology, University of Debrecen, 4032 Debrecen, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laporte</LastName><ForeName>Manon</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5708-1321</Identifier><AffiliationInfo><Affiliation>Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leyssen</LastName><ForeName>Pieter</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-7537-1688</Identifier><AffiliationInfo><Affiliation>Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Research Infrastructure on Highly Pathogenic Agents (ERINHA-AISBL), Rue du Trône 98, 1050 Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neyts</LastName><ForeName>Johan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-0033-7514</Identifier><AffiliationInfo><Affiliation>Laboratory of Virology and Chemotherapy, Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Research Infrastructure on Highly Pathogenic Agents (ERINHA-AISBL), Rue du Trône 98, 1050 Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tőzsér</LastName><ForeName>József</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5076-8729</Identifier><AffiliationInfo><Affiliation>Laboratory of Retroviral Biochemistry, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mahdi</LastName><ForeName>Mohamed</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7959-5996</Identifier><AffiliationInfo><Affiliation>Laboratory of Retroviral Biochemistry, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>TKP2021-EGA-20 (Biotechnology)</GrantID><Agency>Ministry for Innovation and Technology</Agency><Country /></Grant><Grant><GrantID>ÚNKP-23-3-II-DE-456</GrantID><Agency>New National Excellence Program of the Ministry of Culture and Innovation</Agency><Country /></Grant><Grant><GrantID>824061</GrantID><Agency>ERINHA-Advance project (funding from the European Union's Horizon 2020 Research &amp; Innovation Program</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>43Y000U234</RegistryNumber><NameOfSubstance UI="D000068898">Raltegravir Potassium</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019428">HIV Integrase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.-</RegistryNumber><NameOfSubstance UI="D019427">HIV Integrase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068898" MajorTopicYN="Y">Raltegravir Potassium</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015498" MajorTopicYN="Y">HIV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019428" MajorTopicYN="N">HIV Integrase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057809" MajorTopicYN="N">HEK293 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002213" MajorTopicYN="N">Capsid</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019427" MajorTopicYN="N">HIV Integrase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">HIV-2</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">integrase</Keyword><Keyword MajorTopicYN="N">integrase strand transfer inhibitor (INSTIs)</Keyword><Keyword MajorTopicYN="N">lenacapavir</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39459940</ArticleId><ArticleId IdType="pmc">PMC11512360</ArticleId><ArticleId IdType="doi">10.3390/v16101607</ArticleId><ArticleId IdType="pii">v16101607</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>UNAIDS  Global HIV/AIDS Data and Statistics.  [(accessed on 1 September 2024)].  Available online:  https://www.unaids.org/en/resources/fact-sheet.</Citation></Reference><Reference><Citation>Campbell-Yesufu O.T., Gandhi R.T. Update on human immunodeficiency virus (HIV)-2 infection. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2011;52:780–787. doi: 10.1093/cid/ciq248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciq248</ArticleId><ArticleId IdType="pmc">PMC3106263</ArticleId><ArticleId IdType="pubmed">21367732</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb G.S., Raugi D.N., Smith R.A. 90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2. Lancet HIV. 2018;5:e390–e399. doi: 10.1016/S2352-3018(18)30094-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3018(18)30094-8</ArticleId><ArticleId IdType="pubmed">30052509</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceccarelli G., Giovanetti M., Sagnelli C., Ciccozzi A., d’Ettorre G., Angeletti S., Borsetti A., Ciccozzi M. Human Immunodeficiency Virus Type 2: The Neglected Threat. Pathogens. 2021;10:1377. doi: 10.3390/pathogens10111377.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens10111377</ArticleId><ArticleId IdType="pmc">PMC8621479</ArticleId><ArticleId IdType="pubmed">34832533</ArticleId></ArticleIdList></Reference><Reference><Citation>Esbjornsson J., Mansson F., Kvist A., da Silva Z.J., Andersson S., Fenyo E.M., Isberg P.E., Biague A.J., Lindman J., Palm A.A., et al. Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: A prospective open cohort study. Lancet. HIV. 2018;6:e25–e31. doi: 10.1016/S2352-3018(18)30254-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3018(18)30254-6</ArticleId><ArticleId IdType="pubmed">30392769</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutrell J., Jodlowski T., Bedimo R. The management of treatment-experienced HIV patients (including virologic failure and switches) Ther. Adv. Infect. Dis. 2020;7:2049936120901395. doi: 10.1177/2049936120901395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2049936120901395</ArticleId><ArticleId IdType="pmc">PMC6974747</ArticleId><ArticleId IdType="pubmed">32010443</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhuri I., Biswas A., Haldane A., Levy R.M. Contingency and Entrenchment of Drug-Resistance Mutations in HIV Viral Proteins. J. Phys. Chem. B. 2022;126:10622–10636. doi: 10.1021/acs.jpcb.2c06123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jpcb.2c06123</ArticleId><ArticleId IdType="pmc">PMC9841799</ArticleId><ArticleId IdType="pubmed">36493468</ArticleId></ArticleIdList></Reference><Reference><Citation>Nachega J.B., Marconi V.C., van Zyl G.U., Gardner E.M., Preiser W., Hong S.Y., Mills E.J., Gross R. HIV treatment adherence, drug resistance, virologic failure: Evolving concepts. Infect. Disord. Drug Targets. 2011;11:167–174. doi: 10.2174/187152611795589663.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187152611795589663</ArticleId><ArticleId IdType="pmc">PMC5072419</ArticleId><ArticleId IdType="pubmed">21406048</ArticleId></ArticleIdList></Reference><Reference><Citation>Slama L., Porcher R., Linard F., Chakvetadze C., Cros A., Carillon S., Gallardo L., Viard J.P., Molina J.M. Injectable long acting antiretroviral for HIV treatment and prevention: Perspectives of potential users. BMC Infect. Dis. 2023;23:98. doi: 10.1186/s12879-023-08071-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08071-9</ArticleId><ArticleId IdType="pmc">PMC9936705</ArticleId><ArticleId IdType="pubmed">36803606</ArticleId></ArticleIdList></Reference><Reference><Citation>Witvrouw M., Pannecouque C., Van Laethem K., Desmyter J., De Clercq E., Vandamme A.M. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS. 1999;13:1477–1483. doi: 10.1097/00002030-199908200-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00002030-199908200-00006</ArticleId><ArticleId IdType="pubmed">10465070</ArticleId></ArticleIdList></Reference><Reference><Citation>Desbois D., Roquebert B., Peytavin G., Damond F., Collin G., Benard A., Campa P., Matheron S., Chene G., Brun-Vezinet F., et al. In vitro phenotypic susceptibility of human immunodeficiency virus type 2 clinical isolates to protease inhibitors. Antimicrob. Agents Chemother. 2008;52:1545–1548. doi: 10.1128/AAC.01284-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01284-07</ArticleId><ArticleId IdType="pmc">PMC2292533</ArticleId><ArticleId IdType="pubmed">18227188</ArticleId></ArticleIdList></Reference><Reference><Citation>Menendez-Arias L., Alvarez M. Antiretroviral therapy and drug resistance in human immunodeficiency virus type 2 infection. Antivir. Res. 2014;102:70–86. doi: 10.1016/j.antiviral.2013.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.12.001</ArticleId><ArticleId IdType="pubmed">24345729</ArticleId></ArticleIdList></Reference><Reference><Citation>Craigie R. The molecular biology of HIV integrase. Future Virol. 2012;7:679–686. doi: 10.2217/fvl.12.56.</Citation><ArticleIdList><ArticleId IdType="doi">10.2217/fvl.12.56</ArticleId><ArticleId IdType="pmc">PMC3458710</ArticleId><ArticleId IdType="pubmed">23024700</ArticleId></ArticleIdList></Reference><Reference><Citation>Jozwik I.K., Passos D.O., Lyumkis D. Structural Biology of HIV Integrase Strand Transfer Inhibitors. Trends Pharmacol. Sci. 2020;41:611–626. doi: 10.1016/j.tips.2020.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2020.06.003</ArticleId><ArticleId IdType="pmc">PMC7429322</ArticleId><ArticleId IdType="pubmed">32624197</ArticleId></ArticleIdList></Reference><Reference><Citation>Trivedi J., Mahajan D., Jaffe R.J., Acharya A., Mitra D., Byrareddy S.N. Recent Advances in the Development of Integrase Inhibitors for HIV Treatment. Curr. HIV/AIDS Rep. 2020;17:63–75. doi: 10.1007/s11904-019-00480-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11904-019-00480-3</ArticleId><ArticleId IdType="pmc">PMC7004278</ArticleId><ArticleId IdType="pubmed">31965427</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R.A., Raugi D.N., Pan C., Coyne M., Hernandez A., Church B., Parker K., Mullins J.I., Sow P.S., Gottlieb G.S., et al. Three main mutational pathways in HIV-2 lead to high-level raltegravir and elvitegravir resistance: Implications for emerging HIV-2 treatment regimens. PLoS ONE. 2012;7:e45372. doi: 10.1371/journal.pone.0045372.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0045372</ArticleId><ArticleId IdType="pmc">PMC3445448</ArticleId><ArticleId IdType="pubmed">23028968</ArticleId></ArticleIdList></Reference><Reference><Citation>Descamps D., Peytavin G., Visseaux B., Tubiana R., Damond F., Campa P., Charpentier C., Khuong-Josses M.A., Duvivier C., Karmochkine M., et al. Dolutegravir in HIV-2-Infected Patients with Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2015;60:1521–1527. doi: 10.1093/cid/civ124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/civ124</ArticleId><ArticleId IdType="pubmed">25690598</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Hingrat Q., Collin G., Le M., Peytavin G., Visseaux B., Bertine M., Tubiana R., Karmochkine M., Valin N., Collin F., et al. A New Mechanism of Resistance of Human Immunodeficiency Virus Type 2 to Integrase Inhibitors: A 5-Amino-Acid Insertion in the Integrase C-Terminal Domain. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 2019;69:657–667. doi: 10.1093/cid/ciy940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciy940</ArticleId><ArticleId IdType="pubmed">30383215</ArticleId></ArticleIdList></Reference><Reference><Citation>Pujari S., Patel A., Gaikwad S., Patel K., Dabhade D., Chitalikar A., Joshi K., Bele V. Effectiveness of dolutegravir-based antiretroviral treatment for HIV-2 infection: Retrospective observational study from Western India. J. Antimicrob. Chemother. 2020;75:1950–1954. doi: 10.1093/jac/dkaa112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkaa112</ArticleId><ArticleId IdType="pubmed">32277827</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R.A., Raugi D.N., Pan C., Sow P.S., Seydi M., Mullins J.I., Gottlieb G.S., University of Washington-Dakar H.I.V.S.G. In vitro activity of dolutegravir against wild-type and integrase inhibitor-resistant HIV-2. Retrovirology. 2015;12:10. doi: 10.1186/s12977-015-0146-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12977-015-0146-8</ArticleId><ArticleId IdType="pmc">PMC4328052</ArticleId><ArticleId IdType="pubmed">25808007</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R.A., Raugi D.N., Wu V.H., Zavala C.G., Song J., Diallo K.M., Seydi M., Gottlieb G.S., University of Washington-Dakar HIV-2 Study Group Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants. Antimicrob. Agents Chemother. 2019;63:e00014-19. doi: 10.1128/AAC.00014-19.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00014-19</ArticleId><ArticleId IdType="pmc">PMC6496081</ArticleId><ArticleId IdType="pubmed">30803972</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R.A., Wu V.H., Zavala C.G., Raugi D.N., Ba S., Seydi M., Gottlieb G.S., University of Washington-Dakar HIV-2 Study Group In Vitro Antiviral Activity of Cabotegravir against HIV-2. Antimicrob. Agents Chemother. 2018;62:e01299-18. doi: 10.1128/AAC.01299-18.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01299-18</ArticleId><ArticleId IdType="pmc">PMC6153831</ArticleId><ArticleId IdType="pubmed">30012774</ArticleId></ArticleIdList></Reference><Reference><Citation>Link J.O., Rhee M.S., Tse W.C., Zheng J., Somoza J.R., Rowe W., Begley R., Chiu A., Mulato A., Hansen D., et al. Clinical targeting of HIV capsid protein with a long-acting small molecule. Nature. 2020;584:614–618. doi: 10.1038/s41586-020-2443-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2443-1</ArticleId><ArticleId IdType="pmc">PMC8188729</ArticleId><ArticleId IdType="pubmed">32612233</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y., Lambert C., Arendt V., Seguin-Devaux C. Virological and immunological outcomes of elvitegravir-based regimen in a treatment-naive HIV-2-infected patient. AIDS. 2014;28:2329–2331. doi: 10.1097/QAD.0000000000000414.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000000414</ArticleId><ArticleId IdType="pubmed">25313590</ArticleId></ArticleIdList></Reference><Reference><Citation>Roquebert B., Damond F., Collin G., Matheron S., Peytavin G., Benard A., Campa P., Chene G., Brun-Vezinet F., Descamps D., et al. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J. Antimicrob. Chemother. 2008;62:914–920. doi: 10.1093/jac/dkn335.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jac/dkn335</ArticleId><ArticleId IdType="pubmed">18718922</ArticleId></ArticleIdList></Reference><Reference><Citation>Richetta C., Tu N.Q., Delelis O. Different Pathways Conferring Integrase Strand-Transfer Inhibitors Resistance. Viruses. 2022;14:2591. doi: 10.3390/v14122591.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14122591</ArticleId><ArticleId IdType="pmc">PMC9785060</ArticleId><ArticleId IdType="pubmed">36560595</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillim-Ross L., Cara A., Klotman M.E. HIV-1 extrachromosomal 2-LTR circular DNA is long-lived in human macrophages. Viral Immunol. 2005;18:190–196. doi: 10.1089/vim.2005.18.190.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/vim.2005.18.190</ArticleId><ArticleId IdType="pubmed">15802963</ArticleId></ArticleIdList></Reference><Reference><Citation>Thierry S., Munir S., Thierry E., Subra F., Leh H., Zamborlini A., Saenz D., Levy D.N., Lesbats P., Saib A., et al. Integrase inhibitor reversal dynamics indicate unintegrated HIV-1 dna initiate de novo integration. Retrovirology. 2015;12:24. doi: 10.1186/s12977-015-0153-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12977-015-0153-9</ArticleId><ArticleId IdType="pmc">PMC4372172</ArticleId><ArticleId IdType="pubmed">25808736</ArticleId></ArticleIdList></Reference><Reference><Citation>Maehigashi T., Ahn S., Kim U.I., Lindenberger J., Oo A., Koneru P.C., Mahboubi B., Engelman A.N., Kvaratskhelia M., Kim K., et al. A highly potent and safe pyrrolopyridine-based allosteric HIV-1 integrase inhibitor targeting host LEDGF/p75-integrase interaction site. PLoS Pathog. 2021;17:e1009671. doi: 10.1371/journal.ppat.1009671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009671</ArticleId><ArticleId IdType="pmc">PMC8297771</ArticleId><ArticleId IdType="pubmed">34293041</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh P.K., Li W., Bedwell G.J., Fadel H.J., Poeschla E.M., Engelman A.N. Allosteric Integrase Inhibitor Influences on HIV-1 Integration and Roles of LEDGF/p75 and HDGFL2 Host Factors. Viruses. 2022;14:1883. doi: 10.3390/v14091883.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14091883</ArticleId><ArticleId IdType="pmc">PMC9502684</ArticleId><ArticleId IdType="pubmed">36146690</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellaers E., Bhat A., Christ F., Debyser Z. Determinants of Retroviral Integration and Implications for Gene Therapeutic MLV-Based Vectors and for a Cure for HIV-1 Infection. Viruses. 2022;15:32. doi: 10.3390/v15010032.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15010032</ArticleId><ArticleId IdType="pmc">PMC9861059</ArticleId><ArticleId IdType="pubmed">36680071</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh K., Sarafianos S.G., Sonnerborg A. Long-Acting Anti-HIV Drugs Targeting HIV-1 Reverse Transcriptase and Integrase. Pharmaceuticals. 2019;12:62. doi: 10.3390/ph12020062.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph12020062</ArticleId><ArticleId IdType="pmc">PMC6631967</ArticleId><ArticleId IdType="pubmed">31010004</ArticleId></ArticleIdList></Reference><Reference><Citation>Ullah Nayan M., Sillman B., Hasan M., Deodhar S., Das S., Sultana A., Thai Hoang Le N., Soriano V., Edagwa B., Gendelman H.E. Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection. Adv. Drug Deliv. Rev. 2023;200:115009. doi: 10.1016/j.addr.2023.115009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2023.115009</ArticleId><ArticleId IdType="pubmed">37451501</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y.C., Zhang W.L., Zhang R.H., Liu C.H., Zhao Y.L., Yan G.Y., Liao S.G., Li Y.J., Zhou M. The Discovery of Indole-2-carboxylic Acid Derivatives as Novel HIV-1 Integrase Strand Transfer Inhibitors. Molecules. 2023;28:8020. doi: 10.3390/molecules28248020.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/molecules28248020</ArticleId><ArticleId IdType="pmc">PMC10745497</ArticleId><ArticleId IdType="pubmed">38138510</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilead Sciences I. Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living with Multi-Drug Resistant HIV.  [(accessed on 22 December 2022)].  Available online:  https://www.gilead.com/news/news-details/2022/sunlenca-lenacapavir-receives-fda-approval-as-a-first-in-class-twice-yearly-treatment-option-for-people-living-with-multi-drug-resistant-hiv.</Citation></Reference><Reference><Citation>Mahdi M., Motyan J.A., Szojka Z.I., Golda M., Miczi M., Tozser J. Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2’s main protease. Virol. J. 2020;17:190. doi: 10.1186/s12985-020-01457-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-020-01457-0</ArticleId><ArticleId IdType="pmc">PMC7689640</ArticleId><ArticleId IdType="pubmed">33243253</ArticleId></ArticleIdList></Reference><Reference><Citation>Indu P., Rameshkumar M.R., Arunagirinathan N., Al-Dhabi N.A., Valan Arasu M., Ignacimuthu S. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach. J. Infect. Public Health. 2020;13:1856–1861. doi: 10.1016/j.jiph.2020.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2020.10.015</ArticleId><ArticleId IdType="pmc">PMC7587076</ArticleId><ArticleId IdType="pubmed">33168456</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavaco-Silva J., Abecasis A., Miranda A.C., Pocas J., Narciso J., Aguas M.J., Maltez F., Almeida I., Germano I., Diniz A., et al. HIV-2 integrase polymorphisms and longitudinal genotypic analysis of HIV-2 infected patients failing a raltegravir-containing regimen. PLoS ONE. 2014;9:e92747. doi: 10.1371/journal.pone.0092747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0092747</ArticleId><ArticleId IdType="pmc">PMC3969368</ArticleId><ArticleId IdType="pubmed">24681625</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutapea H.M.L., Maladan Y., Widodo Relationship between HIV integrase polymorphisms and integrase inhibitor susceptibility: An in silico analysis. Heliyon. 2018;4:e00956. doi: 10.1016/j.heliyon.2018.e00956.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2018.e00956</ArticleId><ArticleId IdType="pmc">PMC6278726</ArticleId><ArticleId IdType="pubmed">30534615</ArticleId></ArticleIdList></Reference><Reference><Citation>Bercoff D.P., Triqueneaux P., Lambert C., Oumar A.A., Ternes A.M., Dao S., Goubau P., Schmit J.C., Ruelle J. Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir. Retrovirology. 2010;7:98. doi: 10.1186/1742-4690-7-98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-4690-7-98</ArticleId><ArticleId IdType="pmc">PMC3006360</ArticleId><ArticleId IdType="pubmed">21114823</ArticleId></ArticleIdList></Reference><Reference><Citation>Miklossy G., Tozser J., Kadas J., Ishima R., Louis J.M., Bagossi P. Novel macromolecular inhibitors of human immunodeficiency virus-1 protease. Protein Eng. Des. Sel. 2008;21:453–461. doi: 10.1093/protein/gzn022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/protein/gzn022</ArticleId><ArticleId IdType="pmc">PMC2902902</ArticleId><ArticleId IdType="pubmed">18480092</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahdi M., Matuz K., Toth F., Tozser J. A modular system to evaluate the efficacy of protease inhibitors against HIV-2. PLoS ONE. 2014;9:e113221. doi: 10.1371/journal.pone.0113221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0113221</ArticleId><ArticleId IdType="pmc">PMC4242608</ArticleId><ArticleId IdType="pubmed">25419967</ArticleId></ArticleIdList></Reference><Reference><Citation>Jochmans D., Leyssen P., Neyts J. A novel method for high-throughput screening to quantify antiviral activity against viruses that induce limited CPE. J. Virol. Methods. 2012;183:176–179. doi: 10.1016/j.jviromet.2012.04.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2012.04.011</ArticleId><ArticleId IdType="pmc">PMC7112866</ArticleId><ArticleId IdType="pubmed">22575574</ArticleId></ArticleIdList></Reference><Reference><Citation>Boudewijns R., Thibaut H.J., Kaptein S.J.F., Li R., Vergote V., Seldeslachts L., Van Weyenbergh J., De Keyzer C., Bervoets L., Sharma S., et al. Stat2 signaling restricts viral dissemination but drives severe pneumonia in sars-cov-2 infected hamsters. Nature Commun. 2020;11:5838. doi: 10.1038/s41467-020-19684-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-19684-y</ArticleId><ArticleId IdType="pmc">PMC7672082</ArticleId><ArticleId IdType="pubmed">33203860</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterhouse A., Bertoni M., Bienert S., Studer G., Tauriello G., Gumienny R., Heer F.T., de Beer T.A.P., Rempfer C., Bordoli L., et al. SWISS-MODEL: Homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46:W296–W303. doi: 10.1093/nar/gky427.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gky427</ArticleId><ArticleId IdType="pmc">PMC6030848</ArticleId><ArticleId IdType="pubmed">29788355</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E. UCSF Chimera—A visualization system for exploratory research and analysis. J. Comput. Chem. 2004;25:1605–1612. doi: 10.1002/jcc.20084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.20084</ArticleId><ArticleId IdType="pubmed">15264254</ArticleId></ArticleIdList></Reference><Reference><Citation>Sondergaard C.R., Olsson M.H., Rostkowski M., Jensen J.H. Improved Treatment of Ligands and Coupling Effects in Empirical Calculation and Rationalization of pKa Values. J. Chem. Theory Comput. 2011;7:2284–2295. doi: 10.1021/ct200133y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ct200133y</ArticleId><ArticleId IdType="pubmed">26606496</ArticleId></ArticleIdList></Reference><Reference><Citation>Olsson M.H., Sondergaard C.R., Rostkowski M., Jensen J.H. PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. J. Chem. Theory Comput. 2011;7:525–537. doi: 10.1021/ct100578z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ct100578z</ArticleId><ArticleId IdType="pubmed">26596171</ArticleId></ArticleIdList></Reference><Reference><Citation>Case D.A., Betz R.M., Cerutti D.S., Cheatham T.E., III, Darden T.A., Duke R.E., Giese T.J., Gohlke H., Goetz A.W., Homeyer N., et al. AMBER 2016. University of California; San Francisco, CA, USA: 2016.</Citation></Reference><Reference><Citation>Le Grand S., Götz A.W., Walker R.C. SPFP: Speed without compromise—A mixed precision model for GPU accelerated molecular dynamics simulations. Comput. Phys. Commun. 2013;184:374–380. doi: 10.1016/j.cpc.2012.09.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cpc.2012.09.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Salomon-Ferrer R., Gotz A.W., Poole D., Le Grand S., Walker R.C. Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent Particle Mesh Ewald. J. Chem. Theory Comput. 2013;9:3878–3888. doi: 10.1021/ct400314y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ct400314y</ArticleId><ArticleId IdType="pubmed">26592383</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier J.A., Martinez C., Kasavajhala K., Wickstrom L., Hauser K.E., Simmerling C. ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB. J. Chem. Theory Comput. 2015;11:3696–3713. doi: 10.1021/acs.jctc.5b00255.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jctc.5b00255</ArticleId><ArticleId IdType="pmc">PMC4821407</ArticleId><ArticleId IdType="pubmed">26574453</ArticleId></ArticleIdList></Reference><Reference><Citation>Galindo-Murillo R., Robertson J.C., Zgarbova M., Sponer J., Otyepka M., Jurecka P., Cheatham T.E., 3rd Assessing the Current State of Amber Force Field Modifications for DNA. J. Chem. Theory Comput. 2016;12:4114–4127. doi: 10.1021/acs.jctc.6b00186.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jctc.6b00186</ArticleId><ArticleId IdType="pmc">PMC4980684</ArticleId><ArticleId IdType="pubmed">27300587</ArticleId></ArticleIdList></Reference><Reference><Citation>Li P., Merz K.M., Jr. Taking into Account the Ion-induced Dipole Interaction in the Nonbonded Model of Ions. J. Chem. Theory Comput. 2014;10:289–297. doi: 10.1021/ct400751u.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ct400751u</ArticleId><ArticleId IdType="pmc">PMC3960013</ArticleId><ArticleId IdType="pubmed">24659926</ArticleId></ArticleIdList></Reference><Reference><Citation>Jorgensen W.L., Chandrasekhar J., Madura J.D., Impey R.W., Klein M.L. Comparison of Simple Potential Functions for Simulating Liquid Water. J Chem Phys. 1983;79:926–935. doi: 10.1063/1.445869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1063/1.445869</ArticleId></ArticleIdList></Reference><Reference><Citation>Machado M.R., Pantano S. Split the Charge Difference in Two! A Rule of Thumb for Adding Proper Amounts of Ions in MD Simulations. J. Chem. Theory Comput. 2020;16:1367–1372. doi: 10.1021/acs.jctc.9b00953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jctc.9b00953</ArticleId><ArticleId IdType="pubmed">31999456</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisch M.J., Trucks G.W., Schlegel H.B., Scuseria G.E., Robb M.A., Cheeseman J.R., Scalmani G., Barone V., Mennucci B., Petersson G.A., et al. Gaussian 09. Gaussian, Inc.; Wallingford, CT, USA: 2016.</Citation></Reference><Reference><Citation>Zhao Y., Truhlar D.G. The M06 suite of density functionals for main group thermochemistry, thermochemical kinetics, noncovalent interactions, excited states, and transition elements: Two new functionals and systematic testing of four M06-class functionals and 12 other functionals. Theor. Chem. Acc. 2008;120:215–241. doi: 10.1007/s00214-007-0310-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00214-007-0310-x</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayly C.I., Cieplak P., Cornell W., Kollman P.A. A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges: The RESP model. J. Phys. Chem. 1993;97:10269–10280. doi: 10.1021/j100142a004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/j100142a004</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Wang W., Kollman P.A., Case D.A. Automatic atom type and bond type perception in molecular mechanical calculations. J. Mol. Graph. Model. 2006;25:247–260. doi: 10.1016/j.jmgm.2005.12.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmgm.2005.12.005</ArticleId><ArticleId IdType="pubmed">16458552</ArticleId></ArticleIdList></Reference><Reference><Citation>Korb O., Stützle T., Exner T.E. An ant colony optimization approach to flexible protein–ligand docking. Swarm Intell. 2007;1:115–134. doi: 10.1007/s11721-007-0006-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11721-007-0006-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Korb O., Stützle T., Exner T.E. PLANTS: Application of Ant Colony Optimization to Structure-Based Drug Design; Proceedings of the Ant Colony Optimization and Swarm Intelligence; Brussels, Belgium. 4–7 September 2006; Berlin/Heidelberg, Germany: Springer; 2006. pp. 247–258.</Citation></Reference><Reference><Citation>Jumper J., Evans R., Pritzel A., Green T., Figurnov M., Ronneberger O., Tunyasuvunakool K., Bates R., Zidek A., Potapenko A., et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596:583–589. doi: 10.1038/s41586-021-03819-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03819-2</ArticleId><ArticleId IdType="pmc">PMC8371605</ArticleId><ArticleId IdType="pubmed">34265844</ArticleId></ArticleIdList></Reference><Reference><Citation>Mirdita M., Schutze K., Moriwaki Y., Heo L., Ovchinnikov S., Steinegger M. ColabFold: Making protein folding accessible to all. Nat. Methods. 2022;19:679–682. doi: 10.1038/s41592-022-01488-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41592-022-01488-1</ArticleId><ArticleId IdType="pmc">PMC9184281</ArticleId><ArticleId IdType="pubmed">35637307</ArticleId></ArticleIdList></Reference><Reference><Citation>Trott O., Olson A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010;31:455–461. doi: 10.1002/jcc.21334.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcc.21334</ArticleId><ArticleId IdType="pmc">PMC3041641</ArticleId><ArticleId IdType="pubmed">19499576</ArticleId></ArticleIdList></Reference><Reference><Citation>Bester S.M., Adu-Ampratwum D., Annamalai A.S., Wei G., Briganti L., Murphy B.C., Haney R., Fuchs J.R., Kvaratskhelia M. Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir. mBio. 2022;13:e0180422. doi: 10.1128/mbio.01804-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.01804-22</ArticleId><ArticleId IdType="pmc">PMC9600929</ArticleId><ArticleId IdType="pubmed">36190128</ArticleId></ArticleIdList></Reference><Reference><Citation>Cook N.J., Li W., Berta D., Badaoui M., Ballandras-Colas A., Nans A., Kotecha A., Rosta E., Engelman A.N., Cherepanov P. Structural basis of second-generation HIV integrase inhibitor action and viral resistance. Science. 2020;367:806–810. doi: 10.1126/science.aay4919.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aay4919</ArticleId><ArticleId IdType="pmc">PMC7023979</ArticleId><ArticleId IdType="pubmed">32001525</ArticleId></ArticleIdList></Reference><Reference><Citation>Zapata-Cardona M.I., Florez-Alvarez L., Guerra-Sandoval A.L., Chvatal-Medina M., Guerra-Almonacid C.M., Hincapie-Garcia J., Hernandez J.C., Rugeles M.T., Zapata-Builes W. In vitro and in silico evaluation of antiretrovirals against SARS-CoV-2: A drug repurposing approach. AIMS Microbiol. 2023;9:20–40. doi: 10.3934/microbiol.2023002.</Citation><ArticleIdList><ArticleId IdType="doi">10.3934/microbiol.2023002</ArticleId><ArticleId IdType="pmc">PMC9988408</ArticleId><ArticleId IdType="pubmed">36891537</ArticleId></ArticleIdList></Reference><Reference><Citation>Verburgh M.L., van der Valk M., Rijnders B.J.A., Reiss P., Wit F. No association between use of tenofovir disoproxil fumarate, etravirine, or integrase-strand transfer inhibitors and acquisition or severe outcomes of SARS-CoV-2 infection in people with HIV in the Netherlands. Aids. 2023;37:1481–1486. doi: 10.1097/QAD.0000000000003577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000003577</ArticleId><ArticleId IdType="pmc">PMC10328501</ArticleId><ArticleId IdType="pubmed">37395254</ArticleId></ArticleIdList></Reference><Reference><Citation>Prather C., Lee A., Yen C. Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV. Am. J. Health-Syst. Pharm. 2023;80:1774–1780. doi: 10.1093/ajhp/zxad223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajhp/zxad223</ArticleId><ArticleId IdType="pubmed">37767713</ArticleId></ArticleIdList></Reference><Reference><Citation>Bester S.M., Wei G., Zhao H., Adu-Ampratwum D., Iqbal N., Courouble V.V., Francis A.C., Annamalai A.S., Singh P.K., Shkriabai N., et al. Structural and mechanistic bases for a potent HIV-1 capsid inhibitor. Science. 2020;370:360–364. doi: 10.1126/science.abb4808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb4808</ArticleId><ArticleId IdType="pmc">PMC7831379</ArticleId><ArticleId IdType="pubmed">33060363</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Perri G. Pharmacological outlook of Lenacapavir: A novel first-in-class Long-Acting HIV-1 Capsid Inhibitor. Le Infez. Med. 2023;31:495–499. doi: 10.53854/liim-3104-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.53854/liim-3104-8</ArticleId><ArticleId IdType="pmc">PMC10705863</ArticleId><ArticleId IdType="pubmed">38075416</ArticleId></ArticleIdList></Reference><Reference><Citation>Dvory-Sobol H., Shaik N., Callebaut C., Rhee M.S. Lenacapavir: A first-in-class HIV-1 capsid inhibitor. Curr. Opin. HIV AIDS. 2022;17:15–21. doi: 10.1097/COH.0000000000000713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/COH.0000000000000713</ArticleId><ArticleId IdType="pubmed">34871187</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>